The Patent Finder

Jina Pharmaceuticals, Inc.

8 patents currently held · Updated Nov 17, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3
Ending by 2030
Nov 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 13, 2026
    The maintenance fee for Endoxifen methods and compositions for inhibition of protein kinase C (US 11,672,758) comes due Dec 13, 2026. Unpaid by Jun 14, 2027, it lapses early.
  • 1 fee due Feb 13, 2027
    The maintenance fee for Endoxifen compositions and methods (US 10,376,479) comes due Feb 13, 2027. Unpaid by Aug 13, 2027, it lapses early.
  • 1 fee due Nov 10, 2027
    The maintenance fee for Endoxifen compositions and methods (US 9,333,190) comes due Nov 10, 2027. Unpaid by May 10, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 8 of 8

PatentTitleStatus Expires Confidence
US 10,376,479Endoxifen compositions and methods
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,672,758Endoxifen methods and compositions for inhibition of protein kinase C
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,333,190Endoxifen compositions and methods
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,750,812Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,637,515Guggulphospholipid methods and compositions
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,389,413Methods of Preparing Compositions Containing Thymoquinone
In force
 · High confidence
In forceHigh confidence
US 11,291,640Endoxifen for the treatment of bipolar I disorder
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,245,997Endoxifen for the Treatment of Bipolar I Disorder
In force
 · Medium confidence
In forceMedium confidence

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 pending · 1 abandoned · 7 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited